PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Clinical trials for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) explained in plain language.
Never miss a new study
Get alerted when new PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) trials appear
Sign up with your email to follow new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Five-Year Check-Up for rare growth disorder drug
Disease control OngoingThis study is following patients with a rare genetic overgrowth condition (PROS) who are already taking the drug alpelisib. It aims to monitor the long-term safety and effectiveness of the medication over five years. The study is only for people who were in a previous clinical tr…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug trial offers hope for rare, disfiguring growth disorder
Disease control OngoingThis study is testing whether the drug alpelisib can safely reduce abnormal tissue overgrowth in people with a rare genetic condition called PROS. It involves about 200 children and adults. For the first 16 weeks, some participants receive the drug while others receive a placebo,…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC